This filing relates to the resale by the selling securityholders of up to (i) 3.38M ordinary shares and (ii) 7.51M American Depositary Shares, or ADSs, representing 15.02M ordinary shares of Renalytix plc, or the company. The company is not selling any securities and will not receive any proceeds from the sale of the securities.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RNLX:
- Renalytix publishes new real-world evidence on KidneyIntelX utility
- New Published Real-World Evidence Shows KidneyIntelX™ Utility
- Renalytix announces two presentations accepted at National Kidney Foundaton
- Data Supportive of KidneyIntelX Utility in Minorities and Veterans to Be Presented at the National Kidney Foundation Spring Clinical Meeting
- Renalytix price target lowered to $3.50 from $4.00 at BTIG